Aprea Therapeutics Inc.
Aprea Therapeutics, a clinical‑stage biopharma in Doylestown, develops synthetic‑lethality cancer drugs targeting DNA‑damage pathways. Lead assets APR‑1051 (WEE1 inhibitor) and ATRN‑119 (ATR inhibitor) are in phase 1 trials for advanced solid tumors.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 8
- HQ: Doylestown
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.